Mark Gongloff is an editor with Bloomberg Gadfly. He previously was a managing editor of Fortune.com, ran the Huffington Post's business and technology coverage, and was a columnist, reporter and editor for the Wall Street Journal.

Good morning! This is Fly Charts, the daily charts-only newsletter from Gadfly; sign up here. From Abbott Labs' long and winding deal road to AbbVie's star drug, here are four charts that tell you what you need to know in business today.

Narrowing Curve
Steven Mnuchin says Donald Trump's tax plan will spur 3% economic growth. The bond market isn't buying it.
Source: Bloomberg
Taking the Journey
After 20 months of back-and-forth, the Abbott Labs-Alere deal is finally happening. Now the only question is: Was it all worth it?
Source: Bloomberg
Glide Path
AbbVie investors may not yet fully realize just how durable Humira's sales are, now that a big potential competitor has backed down.
Source: Bloomberg
Playing Catch-Up
Picking stocks is hard. It's even harder when you try to chase growth.
Sources: Fama/French, author's calculations

And don't miss Stephen Gandel on why AIG shouldn't be on the government's list of too-big-to-fail institutions: "But taking AIG off the SIFI list is not about forgetting the crisis, it's about correcting a regulation error made in the charged days after the financial system nearly collapsed. AIG should have never been on the SIFI list to begin with." 

This column does not necessarily reflect the opinion of Bloomberg LP and its owners.

To contact the author of this story:
Mark Gongloff in New York at mgongloff1@bloomberg.net